Arterial floating mural thrombi are a characteristic imaging pattern in SARS-CoV-2-related ischemic stroke.

Publication date: Oct 25, 2024

Acute ischemic stroke (AIS) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to explore neurovascular imaging patterns in patients with SARS-CoV-2-related AIS. We retrospectively analyzed clinical and radiological data of patients hospitalized with AIS and a positive PCR test for SARS-CoV-2 prior to AIS onset. The control group comprised of AIS patients from a pre-COVID-19 pandemic period matched for gender and age. Thirty-five SARS-CoV-2-related stroke patients, and 35 controls were included. Fifty-seven percent of SARS-CoV-2 patients had either mild or asymptomatic disease. A distinctive imaging pattern of floating arterial mural thrombus was detected in 5 patients of the SARS-CoV-2 group. In 4 patients thrombus was attached to a stenotic atherosclerotic plaque in the proximal internal carotid artery. In the 5th patient a cardiac CTA showed multiple floating thrombi in the descending aorta. In the control group, floating thrombus was only detected in one patient. Treatment with dual antiplatelet therapy was associated with thrombus dissolution and good clinical outcome. Patients with floating thrombi had a longer time from SARS-CoV-2 diagnosis to stroke onset (mean 7. 4 versus 3. 4 days). Floating arterial mural thrombi attached to atherosclerotic plaques are unique characteristic source of AIS in SARS-CoV-2 patients. They may lead to ischemic stroke in patients with mild or asymptomatic infection up to 1-2 weeks from SARS-CoV-2 diagnosis. Patients with embolic AIS and SARS-CoV-2 diagnosis should perform high resolution cranio-cervical vascular imaging to evaluate floating thrombi as a potential embolic source.

Open Access PDF

Concepts Keywords
Coronavirus Aged
Mild Aged, 80 and over
Pcr COVID-19
Therapy Female
Thirty Humans
Ischemic Stroke
Male
Middle Aged
Retrospective Studies
SARS-CoV-2
Thrombosis

Semantics

Type Source Name
disease MESH ischemic stroke
disease MESH infection
disease MESH COVID-19 pandemic
disease MESH stroke
disease MESH asymptomatic disease
disease MESH thrombus
disease MESH atherosclerotic plaque
disease MESH asymptomatic infection
disease MESH severe acute respiratory syndrome
disease IDO history
disease IDO process
pathway REACTOME Reproduction
disease MESH venous thromboembolism
disease MESH myocardial infarction
disease MESH ischemia
disease MESH venous thrombosis
drug DRUGBANK Sulodexide
disease MESH lacunar infarction
disease MESH hemorrhagic stroke
disease MESH transient ischemic attack
drug DRUGBANK Fibrinogen Human
disease MESH hypercoagulability
disease MESH atherosclerosis
disease MESH etiology
disease MESH stenosis
disease IDO blood
disease MESH cardiovascular risk factors
drug DRUGBANK Estrone sulfate
disease MESH Dyslipidemia
disease MESH Neoplasm
disease MESH hypertension
disease MESH atrial fibrillation
disease MESH ischemic heart disease
disease MESH infarction
disease MESH sepsis
disease MESH pneumonia
disease MESH embolic stroke
disease MESH cytokine storm
disease MESH critically ill
drug DRUGBANK Beroctocog alfa
drug DRUGBANK Von Willebrand Factor Human
disease MESH immobilization
disease MESH hypoxia
drug DRUGBANK Indoleacetic acid
disease MESH thromboembolism
disease MESH embolism
disease MESH Hemiplegia
disease MESH aphasia
drug DRUGBANK Alteplase
disease MESH paresis
drug DRUGBANK Diaminopropanol tetraacetic acid
disease MESH diabetes mellitus
disease MESH hyperlipidemia
disease MESH cerebral embolism
disease MESH sclerosis
drug DRUGBANK Methyl isocyanate
disease IDO symptom
disease MESH complications
disease IDO quality
disease MESH death
disease IDO intervention
disease MESH recurrence
drug DRUGBANK Heparin
disease MESH carotid stenosis
disease MESH lifestyle factors
drug DRUGBANK Tretamine
drug DRUGBANK L-Valine
disease MESH Neurologic manifestations
disease MESH influenza
disease MESH abnormalities
pathway REACTOME Hemostasis

Original Article

(Visited 1 times, 1 visits today)